Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD

Area of Science:

• Pulmonary Medicine
• Respiratory Research
• Biomarker Discovery

Background:

• Fractional exhaled nitric oxide (FeNO) is a potential non-invasive biomarker for airway inflammation in Chronic Obstructive Pulmonary Disease (COPD).
• Its clinical utility in differentiating COPD subgroups remains controversial and requires further investigation.

Purpose of the Study:

• To evaluate the usefulness of FeNO in assessing airway inflammation across distinct clinically meaningful subgroups of COPD patients.
• To determine if FeNO parameters, including diffusion capacity (D), alveolar NO concentration (Calv), and airway wall NO concentration (Caw), vary significantly among COPD subgroups.

Main Methods:

• FeNO was measured at multiple flow rates (10-200 mL/s) in 91 COPD patients.
• A two-compartment model estimated D, Calv, and Caw.
• Patients were categorized into subgroups based on emphysema severity, chronic bronchitis, exacerbation frequency, and body composition. Advanced non-linear mixed models were employed.

Main Results:

• Modelled differences in D, Calv, and Caw among COPD subgroups were minimal and not statistically significant.
• Current smoking status significantly affected Caw, and gender influenced D and Calv.
• Results remained consistent when using standard analysis techniques.

Conclusions:

• FeNO's relevance as a biomarker for local inflammation in COPD is questionable.
• Novel non-invasive biomarkers are needed for both research and clinical practice in COPD management.